Loading patent…
AssigneesChugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
InventorsMika Endo, Atsuhiko Kato, Toshihiko Ohtomo, Kenji Adachi, Yasuko Kinoshita, Yoshinori Narita
Estimating the term…
The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.
A method for treating or delaying progression of cancer in an individual, comprising administering a therapeutically effective amount of an anti-GPC3 antibody to the individual, wherein the individual is also being administered atezolizumab, wherein the anti-GPC3 antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:42, HVR-H2 sequence of SEQ ID NO:
A method for treating or delaying progression of cancer in an individual, comprising administering to the individual a therapeutically effective amount of an anti-GPC3 antibody, and administering a therapeutically effective amount of atezolizumab, wherein the anti-GPC3 antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:42, HVR-H2 sequence of SEQ ID NO:
A method for treating or delaying progression of cancer in an individual, comprising administering a therapeutically effective amount of atezolizumab to the individual, wherein the individual is also being administered a therapeutically effective amount of an anti-GPC3 antibody, wherein the anti-GPC3 antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:42, HVR-H2 sequence of SEQ ID NO:
Dependencies are inferred from the claim text.